Le Lézard
Classified in: Health, Science and technology
Subjects: WOM, TRI, FDA

ConTIPI Medical Has Received FDA Approval for the Marketing of a Unique Product for the Treatment of Pelvic Organ Prolapse in Women


CAESAREA, Israel, July 9, 2019 /PRNewswire/ -- This week, ConTIPI Medical Ltd. received US Food and Drug Administration (FDA) approval to market its new product, the first of its kind, designed to treat pelvic prolapse in women (such as the uterus and bladder).

Dr. Ilan Ziv, founder and CEO of the Company, an expert in gynecology and urogynecology

The Company was founded in 2014 by Dr. Elan Ziv, founder and CEO of the Company, an expert in gynecology and urogynecology, who developed and sold the Company's first product to Kimberly-Clark Worldwide, and is also invested in the Company, and by Zeev Bronfeld, who is well known for his activity in the area of biotechnology, and is also invested in the Company. Other investors include Boris Krasny, Capital Point Ltd. and Neopharm Ltd. More than $ 13 million has been invested in the Company to date.

ConTIPI Medical Ltd. is an Israeli biotechnology company that develops disposable and non-invasive devices for the treatment of pelvic floor dysfunctions in women, and has so far developed 2 major products from its patent portfolio. The first product designed to treat stress urinary incontinence was sold in 2013 to Kimberly Clark Worldwide and is now available for sale off the shelf in North America. The second product, which has been under development for more than four years, is intended for the treatment of pelvic organ prolapse, received two years ago a European sales permit (CE) and now has also received FDA clearance in the United States.

The Company's developments are a major breakthrough in a market that has been largely neglected in recent years and has lacked any significant clinical innovations in the last 20 years. Experts estimate that there are more than 100 million women in the world with some degree of pelvic prolapse, of which about 10 million are women who symptomatic and are interested in diagnosis and treatment. The market for treatment of pelvic organ prolapses is now estimated at $ 20 billion a year, but is expected to grow significantly in the next few years due to increased awareness among women and the aging of the population. The Company's products are a social "revolution", since they enable the transfer of control over the medical problem to women, in a completely discreet manner, with only limited involvement of the medical system. It is the patient who decides on the treatment and its availability, and uses the device (similar to the insertion of a tampon) at a convenient time and place.

Dr. Elan Ziv, founder and CEO of the Company, notes: "For many years we have been working to promote pelvic floor solutions and products that will help every woman conduct a normal life and fully control her medical condition. This is an innovative groundbreaking product, enabling women to control their medical problem and we assume that the product will soon be available to millions of women worldwide who would be interested in treatment."

For further information: Hofit@pr360.co.il, +97235449494

 

The new product, designed to treat pelvic prolapse in women (such as the uterus and bladder).

SOURCE ConTIPI Medical Ltd


These press releases may also interest you

at 03:00
Video surveillance and alarm systems can help protect homes and businesses and give the occupants peace of mind. Hansen Enterprises, the Paso Robles alarm company, has recently released a report about the added security that comes with video...

4 jui 2020
From 9 July to 11 July 2020, the World Artificial Intelligence Conference (WAIC) will be held online due to the COVID-19 pandemic. Organized by the Shanghai Municipal People's Government, the annual conference's mission is to provide a global...

4 jui 2020
tourHQ, the global marketplace connecting travellers with tour guides around the world has been expanding its repertoire of Online Travel Experiences continuously since its launch in May 2020. These experiences allow clients to travel virtually from...

4 jui 2020
Gilead Sciences, Inc. today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company's investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained...

4 jui 2020
Gilead Sciences, Inc. today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed...

4 jui 2020
80.5% of BBB Accredited charities anticipate that their 2020 revenue will be lower than expected and are searching for new ways to engage Millennials and Generation Z donors.  Only 19% of people highly trust charities according to a Donor Trust...



News published on 9 july 2019 at 09:19 and distributed by: